Background We aim to compare the diameters of ascending aorta in COVID-19 patients and COVID–19-free individuals referred to our pandemic hospital. Methods The medical records and thorax tomographies of patients admitted to the “pandemic central” state hospital with symptoms of COVID-19 were observed between April 2020 and May 2020 in this case-control study. The first group consisted of patients diagnosed with COVID-19, and the second group consisted of patients without the disease. The diameter of the ascending aorta is measured via tomography and compared to each other. The most causative risk factors for aortic enlargements underwent a multivariate regression analysis. Results Charts of 156 patients (104 COVID-19 positives, 52 COVID-19 negatives) were reviewed. There was a statistical difference ( p: .01) between the mean aortic diameter of COVID-19 patients (39 mm) and COVID-free patients (32.5 mm) even though comorbid factors and patient characteristics were similar in the two groups at the time of hospital admission. The regression analysis result demonstrates that COVID-19 (leading factor), age, and coronary artery disease were the most significant factors associated with increasing aortic dimensions. ( p: .001, B: 5.3/, p: .02, B: 3.36/, p: .002, B: 0.13/, R square: 40.2%). Conclusion This study shows that the mean aortic diameter of COVID-19 patients is larger than non–COVID-19 patients with similar comorbidities referred to a pandemic hospital. COVID-19, age, and coronary artery disease are the most influential factors that affect the aortic diameter, and the COVID-19 was the leading factor.
Objectives: The aim of the study was to clarify the reliability and quality of English videos about Coronary artery bypass grafting on YouTubeTM. Methods: The study was performed between July 16 and July 30. A cardiovascular surgeon searched for terms including “coronary artery disease,” “coronary artery treatment,” “coronary artery bypass” and “coronary artery bypass surgery,” in YouTubeTM. All videos were classified into two groups according to the source who uploaded the video as professional videos and non-professional videos. Video characteristics including duration of video on YouTube™, length of video, and view numbers for each video were recorded. Moreover, the numbers of “comments,” “likes,” and “dislikes” were noted. Furthermore, the target audience of the videos (professional health care worker and patients) was analyzed, DISCERN score and Global quality score (GQS) were calculated for each video. Results: Totally, 812 videos were divided into two groups according to upload sources; 448 videos were categorized as professional videos and 364 videos were categorized as non-professional videos. The mean number of views was 3220.5 for professional videos and 2216.5 for non-professional videos (p=0.001). In addition, the mean “like” numbers and mean comment numbers were significantly higher for professional videos (p=0.001 and p=0.001). The mean DISCERN score was 2.6 for professional videos and 1.5 for non-professional videos (p=0.001). Similarly, the mean GSQ was significantly higher for professional videos (3.5 vs. 2.5, p=0.001). Conclusion: YouTube™ videos which are shared by professional healthcare workers have better quality and reliability with significantly higher DISCERN score and GQS.
Objectives The aim of the study was to clarify public interest about cardiovascular disease during the COVID-19 pandemic using Google Trends (GT). Methods The study was performed between November 20 and December 1, 2021. A total of 21 keywords related to cardiovascular surgery were selected. Public attention to all selected keywords was analyzed by GT with using the filters “web search,” “all categories,” and “Turkey.” In Turkey, three COVID-19 waves (between March 12, 2020, and May 8, 2020, November 24, 2020, and January 20, 2021, and March 20, 2021, and May 16, 2021) were experienced since the beginning of the pandemic. To analyze public attention to cardiovascular surgery during the COVID-19 waves, 8-week periods during the COVID-19 waves were compared with the same times in the past 4 years (2016–2019). Results Comparisons of March 12–May 8 2020 and the same period between 2016 and 2019 showed that total public interest about cardiovascular surgery was significantly decreased (−28.7%, p=0.001). The comparison of the second COVID-19 wave (November 24, 2020–January 20, 2021 versus November 24-January 20, 2016–2019) revealed that public interest about cardiovascular surgery was significantly lower in the COVID-19 era (−22.2%, p=0.001). Comparison of the third COVID-19 wave and the same periods in the previous 4 years demonstrated that public interest about cardiovascular disease was significantly lower in the COVID-19 era (−8.5%, p=0.001). In contrast, the term coronary angiography was searched significantly more during the third wave of COVID-19 in comparison to the same periods between 2016 and 2019 (17.9%, p=0.015). Conclusion Our study demonstrated that public interest in cardiovascular diseases was significantly decreased in all waves of the COVID-19 pandemic. However, interest in only the term coronary angiography was significantly increased in the third wave of pandemic.
Background: Coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy presented with venous thromboembolism and arterial thromboses. The aim of this study was to evaluate the effect of routine thromboprophylaxis with low molecular weight heparin (LMWH) on clinical outcomes including mortality and need for intensive care unit (ICU) admission in hospitalized COVID-19 patients. Methods: All confirmed patients with COVID-19 hospitalized to COVID-19 dedicated wards, from March 15 to May 15, 2020, were included in this retrospective cohort study. Two groups of patients were established, according to the non-routine and routine application of LMWH with therapeutic, weight-based, anticoagulation dosing. Clinical, laboratory and treatment data were collected, analyzed and compared between the two groups. A logistic regression model was developed to assess the factors related to in-hospital adverse outcomes. Results: A total of 1511 patients (797 men, median age 59.0 years) were retrospectively analyzed (Group non-routine LMWH (n=828); group routine LMWH (n=683)). Multivariate logistic regression analysis showed routine use of LMWH, favipiravir administration, extreme values of WBC count, NLR, and troponin I as factors independently associated with in-hospital adverse outcomes (OR=0.25, 95% CI: 0.83-0.91; p<0.001 for routine use of LMWH). Conclusion: Routine thromboprophylaxis with LMWH reduced mortality and ICU admission in patients admitted with COVID-19 infection.
Background: Coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy presented with venous thromboembolism and arterial thromboses. The aim of this study was to evaluate the effect of routine thromboprophylaxis with low molecular weight heparin (LMWH) on clinical outcomes including mortality and need for intensive care unit (ICU) admission in hospitalized COVID-19 patients. Methods: All confirmed patients with COVID-19 hospitalized to COVID-19 dedicated wards, from March 15 to May 15, 2020, were included in this retrospective cohort study. Two groups of patients were established, according to the non-routine and routine application of LMWH with therapeutic, weight-based, anticoagulation dosing. Clinical, laboratory and treatment data were collected, analyzed and compared between the two groups. A logistic regression model was developed to assess the factors related to in-hospital adverse outcomes. Results: A total of 1511 patients (797 men, median age 59.0 years) were retrospectively analyzed (Group non-routine LMWH (n=828); group routine LMWH (n=683)). Multivariate logistic regression analysis showed routine use of LMWH, favipiravir administration, extreme values of WBC count, NLR, and troponin I as factors independently associated with in-hospital adverse outcomes (OR=0.25, 95% CI: 0.83-0.91; p<0.001 for routine use of LMWH). Conclusion: Routine thromboprophylaxis with LMWH reduced mortality and ICU admission in patients admitted with COVID-19 infection.
Objective To compare the efficiency and safety of radiofrequency ablation (RFA) and saphenous vein stripping (SVS) for the treatment of recurrent lower extremity chronic superficial venous insufficiency (CSVI). Methods Patients who underwent SVS and RFA for recurrent lower extremity CSVI following RFA and patients who had 2-year follow-up results were enrolled into the study. Total, 37 patients who underwent a second RFA session with 2-year follow-up results were available. Then 37 patients were selected from 88 patients who underwent SVS for recurrent lower extremity CSVI to achieve a 1:1 ratio for comparison. Groups were compared based on preoperative properties, operative parameters, postoperative outcomes, complications and follow-up results. Results Duration of the procedure was 20.7 minutes in the RFA group and 30.7 minutes in the SVS group (P = .001). Postoperative pain at first hour, sixth hour and 24th hour were significantly lower in patients who underwent RF (P = .001 for each parameter). Moreover, hospitalization time (18.1 hours vs 24.6 hours, P = .001) and time to return to normal daily activities (1.6 days and 2.5 days, P = .001) were significantly shorter in the RFA group. Success of the procedure did not statistically significant at first year follow-up (P = .304). However, success was significantly higher for the SVS group at second year follow-up (73% for RFA group and 91.9% for SVS group, P = .032). Conclusion We achieved significantly shorter procedure time, less postoperative hospitalization time, and a shorter time to return to daily activities with RFA. In contrast, the success rate of SVS was significantly higher at the second year follow-up, but not the first year follow-up in comparison with RFA.
Introduction: Troponin I levels are the most important predictive marker of myocardial injury. Myocardial injury has been reported as the most significant cause of morbidity and mortality in pediatric cardiac surgery. In this study, we aimed to evaluate the effect of troponin I on postoperative mortality and morbidity in the child population. Patients and Methods:Ninety-nine patients to whom congenital cardiac surgery were included in this study. Perioperative and postoperative troponin I values at 24 th and 48 th hours were recorded. Patients were divided into two groups according to troponin I values at 24 th hour (lower and higher than 15 ng/mL, respectively). Aortic cross-clamp time, cardiopulmonary bypass (CPB) time, intubation time, and the duration of intensive care unit stay and medication of inotropic agents were recorded.Results: Postoperative troponin I levels at 24 th hour were higher than 15 ng/mL in patients who underwent congenital cardiac surgery and were related with significantly higher CPB, aortic cross-clamp, intubation time, and longer stay in intensive care unit. Conclusion:Higher troponin I levels at 24 th hour are associated with increased morbidity in patients who undergo congenital cardiac surgery. Hastalar ve Yöntem:Konjenital kardiyak cerrahi uygulanan 99 hastanın perioperatif, postoperatif 24. ve 48. saatteki troponin I değerleri kaydedildi. Hastalar hesaplanan cut off değerine göre 24. saat troponin I seviyelerine göre iki gruba ayrıldı (15 ng/mL'den yüksek olanlar ve olmayanlar). Hastaların aortik kros klemp süreleri, kardiyopulmoner baypas süresi, entübasyon süresi, yoğun bakımda kalış süresi ve inotropik ajan düzeyleri kaydedildi. Bulgular: Konjenital kalp ameliyatı olan hastalarda postoperatif 24. saatte ölçülen troponin I seviyelerinin 15 ng/mL'nin üzerinde olmasının: kardiyopulmoner baypas süresi, aortik kross klamp süresi, entübasyon süresi ve yoğun bakım kalış süresini anlamlı olarak arttırdığı gösterildi.Sonuç: Konjenital kalp ameliyatı olan hastalarda postoperatif 24. saat yüksek troponin I düzeyleri yüksek morbidite riski ile uyumludur.
The aim of this study was to analyze percutaneous thrombectomy (PT) outcomes for the management of lower extremity deep vein thrombosis (DVT) with medium-term follow-up. MethodsThe study included charts of patients who underwent PT due to lower extremity DVT between August 2017 and March 2021. Patient characteristics and procedure outcomes were recorded in the electronic information system on the same day as the procedure. The procedures with complete removal of thrombus following PT without requiring additional procedure or additional thrombectomy apparatus were considered successful. Also, duration of follow-up was noted. ResultsIn total, 112 patients were enrolled in the study. The femoropopliteal (40.2%) and iliofemoral (25.0%) veins were the most common sites with thrombus detected. The duration of PT procedure and fluoroscopy were 123.1 minutes and 21.9 minutes, respectively. Estimated blood loss was 255.1 milliliters. The hospital stay and intensive care unit stay following PT were 3.7 and 1.4 days, respectively. Major hemorrhage did not occur in any patient, but we encountered bradycardia in six (5.4%) patients, acute renal failure in one (0.9%) patient, hemoglobinuria in 11 (9.8%) patients, leg pain in 15 (13.4%) patients, and pulmonary embolism in 2 (1.8) patients, respectively. Success of the present study was 94.6% in the first month, and re-operation was required only in one patient. The mean follow-up period was 21.1 months with 90.2% venous patency rates. ConclusionThe present study demonstrated that PT was an effective and reliable treatment modality with acceptable complication rates for the treatment of lower extremity DVT. Additionally, the efficacy of PT was proven by mid-term follow-up results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.